Actinium Pharmaceuticals, Inc.
ATNM · AMEX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | -$0 | -$0 | -$0 | -$0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | -128.9% | – | – | – |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -5,472.2% | – | – | – |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -5,701.1% | – | – | – |
| EPS Diluted | -0.16 | -0.22 | -0.51 | -0.21 |
| % Growth | 27.3% | 56.9% | -142.9% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |